Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners

por Reed, Mollie, Rosales, Aimee-Lauren S., Chioda, Marc D., Parker, Lindsey, Devgan, Geeta, Kettle, Jacob
Publicado 2020

Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study

por Reynolds, Craig, Masters, Elizabeth T., Black-Shinn, Jenny, Boyd, Marley, Mardekian, Jack, Espirito, Janet L., Chioda, Marc
Publicado 2018

Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer

por Waterhouse, David M., Espirito, Janet L., Chioda, Marc D., Baidoo, Bismark, Mardekian, Jack, Robert, Nicholas J., Masters, Elizabeth T.
Publicado 2020

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer

por Barrows, Stephanie M, Wright, Kelly, Copley-Merriman, Catherine, Kaye, James A, Chioda, Marc, Wiltshire, Robin, Torgersen, Knut Martin, Masters, Elizabeth T
Publicado 2019